(Q39840177)

15 September 2017

title

Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program (English)

1 reference

prostate cancer screening

15 September 2017

main subject

1 reference

4

1 reference

15 September 2017

Scott E Eggener

1

1 reference

15 September 2017

Ofer Yossepowitch

2

1 reference

15 September 2017

Kimberly A Roehl

3

1 reference

15 September 2017

Xiaoying Yu

5

1 reference

15 September 2017

William J Catalona

6

1 reference

15 September 2017

language of work or name

English

0 references

publication date

21 March 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

71

1 reference

15 September 2017

issue

6

1 reference

15 September 2017

page(s)

1016-1019

1 reference

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Combining longitudinal studies of PSA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Rate of Change in Serum Prostate Specific Antigen Levels as a Method For Prostate Cancer Detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Prostate-specific antigen as predictor of prostate cancer in black men and white men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Does PSA velocity predict prostate cancer in pre-screened populations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

The association between total prostate specific antigen concentration and prostate specific antigen velocity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Assessment of diagnostic tests when disease verification is subject to selection bias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Testing for fetal pulmonary maturity: ROC analysis involving covariates, verification bias, and combination testing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.008

10.1016/J.UROLOGY.2007.12.008

7 January 2021

Identifiers

DOI

1 reference

release_ucyyxd4g2zgipni3bsh77visgm

15 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ucyyxd4g2zgipni3bsh77visgm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference